COVID-19 Clinical Trials
A Multicenter, Prospective, Randomized, Open-Label Phase 2 Study to Assess Safety and Efficacy of Ang-3777 in Patients Hospitalized With Confirmed COVID-19 Pneumonia.
A Multicenter, double blind, parallel design, placebo controlled trial to Assess Safety and Efficacy of Mesenchymal stem cells for the treatment of moderate to severe COVID-19 acute respiratory distress syndrome.
Richard J. Castriotta
A multicenter, double-blind, randomized controlled trial of a new antiviral drug for COVID-19.
Phase II study of anti-inflammatory/antiviral therapy in moderate-severe pre-ventilator COVID-19.
A5395: A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons with COVID-19.
Multicenter, Randomized-Controlled Trial to Evaluate the Efficacy and Safety of Antithrombotic Therapy for Prevention of Arterial and Venous Thrombotic Complications in Critically Ill COVID-19 Patients
The I-SPY COVID TRIAL is a platform trial providing access to investigational agents for critically ill patients infected with SARS-CoV-2 who have severe or life-threatening COVID-19. The primary endpoint will be time to reach COVID level 4 or less.
An open-label, pilot study followed by a randomized phase II trial of antiviral therapy combined with baricitinib or antivirals alone in moderate and severe patients with COVID-19.
A Phase 3, Randomized, Placebo-Controlled Study of Lenzilumab in Hospitalized Patients with COVID-19 Pneumonia.
A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome
A phase 3 randomized placebo controlled study to examine the efficacy and safety of DAS181 for the treatment of lower respiratory tract parainfluenza infection in the immunocompromised subjects.
Developing peptide treatment for COVID-19 pneumonia. Completed Phase 1 PK and safety studies.
A Phase II, Open-Label, Randomized, Multicenter Study to Investigate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of 8 MG/KG or 4 MG/KG Intravenous Tocilizumab in Patients With Moderate to Severe COVID-19 Pneumonia